# Qualifications Profile

Detail-oriented and versatile medical practitioner, offering comprehensive experience in human eye diseases treatment and care; complemented with broad knowledge of retina, vitreoretinal, ocular, and cataract surgeries. Seeking an opportunity to utilize and develop skills acquired from work experience, research projects, and academic background. Bilingual in Arabic and English; competent at building and maintaining positive relationships with patients and other medical professionals.

# Core Competencies

***Ophthalmology***

***Vision Therapy***

***Macular Degeneration Diagnosis***

***Research and Development***

***Visual Science***

***Regulatory Compliance***

# Education and Credentials

**Bachelor of Medicine, Bachelor of Surgery (MBBS)**, *2004*

Jordan University of Science and Technology – Faculty of Medicine, Irbid, Jordan

*Graduated Fourth Rank*

**Full Medical License**, *State of Texas*, Valid Until August 2020

**Licensed Ophthalmologists**, Valid Until: unlimited

Jordanian Board of Ophthalmology

**Step 3 United States Medical Licensing Examination (USMLE)**, *Passed, 2011*

**Step 2 Clinical Skills (CS)**, *Passed, 2009*

**Step 2 Clinical Knowledge (CK)**, *Passed, 2008*

**Step 1 United States Medical Licensing Examination (USMLE)**, *Passed, 2005*

United States Medical Licensing Examination (USMLE)

**Permanent Certification**, *2009*

Educational Commission for Foreign Medical Graduates (ECFMG)

**Part 1 Examination with Merit Degree**, *Passed, 2007*

International Council of Ophthalmology (ICO)

**Permanent Medical License**, *2005*

Ministry of Health, Amman, Jordan

# Clinical Experience

## King Abdullah University Hospital, Ramtha, Jordan

### **Retina and Cataract Surgeon** *2012–Present*

## Shami Eye Center, Irbid, Jordan

### **Retina and Cataract Surgeon**  *2012–Present*

## The University of Texas Health Science Center at Houston, Houston, TX, USA

### **Vitreoretinal Fellow** *2010–2012*

## King Abdullah University Hospital - Jordan University of Science and Technology, Ramtha, Jordan

### **Chief Resident**, *Ophthalmology* *2008–2009*

## King Abdullah University Hospital, Ramtha, Jordan

### **Resident**, *Ophthalmology* *2005–2009*

## St. Joseph Medical Center, Houston, TX, USA

### **Intern**, *Retina* *2009*

## King Abdullah University Hospital, Ramtha, Jordan

### **Intern**, *Multidisciplinary* *2004–2005*

# Leadership Experience

## Jordan University of Science and Technology, Irbid, Jordan

### **Head of Ophthalmology Division** *2015–2016*

### **Assistant Dean**, *Faculty of Medicine* *2014–2015*

# Teaching Experience

## Jordan University of Science and Technology, Irbid, Jordan

### **Assistant Professor**, *Faculty of Medicine* *2014–Present*

### **Assistant Professor**, *Department of Ophthalmology and Visual Sciences* *2012–Present*

### **Teaching Assistant** *2009–2010*

# Research Experience

## Jordan University of Science and Technology, Irbid, Jordan

### **Research Assistant** *2009–2010*

# Professional Development

**Higher Specialty in Ophthalmology Training**, *2009*

King Abdullah University Hospital (KAUH) - Jordan University of Science and Technology (JUST)

# Awards

**International Council Scholarship**, *2007*

International Council of Ophthalmology

# Professional Affiliations

Jordanian Medical Association

American Academy of Ophthalmology (AAO)

# Activities

**Participant** | 2nd Gulf Novartis Advisory Board, Kuwait, Kuwait

**Speaker** | 1st Jordanian Retina Day in 2014, Amman, Jordan

**Attendee** | Jordanian Ophthalmologic Society Meeting in 2013 and 2016, Amman

**Attendee** | European Society of Retina Specialists (EURETINA) Meeting, 2016, 2018

American Academy of Ophthalmology annual meeting2010, 2016, 2017, 2019

**Coordinator** | Medical School Graduate Reunion - Jordan University of Science and Technology (JUST), Irbid, Jordan

# Research Projects

### ***Project Name:* Paclitaxel and its Effects in Developing Cystoids Macular Edema**

***Role***: Primary investigator

***Other Collaborators***: Osama Al Sharei and Mohammad Basuleiman

***Company Name***: King Abdullah University Hospital

***Objective***: To determine if paclitaxel is associated with developing cystoids macular edema

***Background***:

Paclitaxel is an anticancer drug and one of the most common used in treating numerous types of cancer. It is a cytotoxic drug with the ability to stabilize microtubules and reduce its dynamicity to promote mitotic halt and cell death. It may cause some unwanted effects, such as myelosuppression, hair loss, arthralgia, peripheral neuropathy, nausea, vomiting, diarrhea, and mouth ulcers.

Cystoid macular edema (CME) is a painless disorder, in which swelling develops in the macula. As the swelling increases, multiple fluid filled cysts develop in macula which can cause vision loss and distortion. This occurs due to disruption of normal blood-retinal barrier, resulting in leakage from the perifoveal retinal capillaries and accumulation of fluid within the intracellular spaces of the retina. The main causes are eye surgery, diabetic retinopathy, retinal vein occlusion, and age-related macular degeneration and inflammation. It is usually diagnosed through various ways, such as dilated eye examination, a retinal scan called optical coherence tomography (OCT), and fluorescein angiography.

***Innovative Discovery***:

* Conducted thorough analysis of 50 patients undergoing cancer treatment, wherein paclitaxel is part of their chemotherapy. This involves facilitating eye examinations and taking optical coherence tomography (OCT) images. The result of this effort will lead to better understanding of the effect of paclitaxel on macular thickness and the risk of developing cystoid macular edema in these patients.

### ***Project Name: ocular hemorrhage in patients with thrombocytopenia due to different etiologies***

***Role***: primary investigator

***Other Collaborators***: Dr. Mahmoud Ayesh, Dr. Omar Mulki, and Hala Alayoubi

***Client Name***: King Abdullah University Hospital

***Objective***: To describe the coordination between different types of ocular hemorrhage in patient with thrombocytopenia due to varied hematological disorder

***Background***:

Anemia is a decrease in number of circulatory RBC or decrease in hemoglobin content of each cell, while thrombocytopenia is reduction in number of platelet. Retinopathy is usually an incidental finding, although findings increase with severity of anemia in coexisting thrombocytopenia. Most studies reported the correlation between patients with hematological pathology with ocular hemorrhage.

Patients from the Internal Medicine Department diagnosed with thrombocytopenia secondary to various hematological disorders were referred for complete eye examination, including visual acuity assessment, eye anterior and posterior segment examination, and hemorrhage documentation that is present in any ocular structure with particular attention to retinal hemorrhage. Findings were documented by taking photographs for either anterior or posterior segment hemorrhage. Patients were categorized in accordance with their primary diagnosis and level of platelet with ocular hemorrhage findings.

***Innovative Discovery***:

* Identified a different platelet level for different type of hematological disorder which ocular hemorrhage could be detectable.

# Articles

Jammal, H.M. and **Mohidat, H.M.** (2010). Toxoplasma retinitis presenting with macular neurosensory detachment. *American Journal of Case Reports*, *11*, 208–210.

Shihadeh, W.A. and **Mohidat, H.M.** (2012). Outcome of Boston Keratoprosthesis in Jordan. *Middle East African Journal of Ophthalmology, 19*(1), 97–100.

Ponce, C.M.P., **Mohidat, H.M.**, and Garcia, C.A. (2012). Central serous chorioretinopathy after blunt trauma. *BMJ Case Reports*,

# Presentation

**Mohidat, H.M.** (2015). *Age-related macular degeneration*. Gulf Nurse Retina Master Class, Amman, Jordan.

**Mohidat, H.M.** (2016). *How to best diagnose DME early*. Paper presented at the Focus Meeting of Bayer, Dubai, UAE.

**Mohidat, H.M.** (2016). *Safety of anti-VEGF therapy*. Paper presented at the DME Advisory Board Meeting of Novartis, Amman, Jordan.